V-CLAMP

Product Introduction

Transapical approach



Transapical implantation. The catheter manipulation time is about 20 minutes. Shorter operative time, lower operative risk.

Minimal invasive surgery



Cardiopulmonary bypass is not required. Less trauma and complication Rapid. post-operative recovery.

Precisely capture leaflet



Smaller-sized delivery system (14F).

Different size of devices can be provided for different mitral annular size and MR pattern.

Multiple clips can be implanted for reducing residual MR.

Echo-guided Image



Procedural guiding of the V-clamp implantation with 2D and 3D transesophageal echocardiography (TEE). X-ray fluoroscopy is not necessary.



TREATMENT OF PET CARDIAC DISEASE

Leading canine mitral valve interventional device with proven safety and effectiveness in the world



Website: www.hongyumedtechglobal.com

Address: Building 1, No. 3699 Yuanjiang Road,

Minhang District, Shanghai

Email: customer_service@hongyumedtech.com



instagram



wechat



INTRODUCTION

Based on the transcatheter edge—to—edge mitral valve repair, mitral valve clamping system has been widely used in human and proved to be safe and effective. Through the minimally invasive method on the body surface, a clamp is implanted through the apex of the pet dog. After clamping, the valve is in the shape of a double hole, which reduces the area of regurgitation and achieves the therapeutic effect.

V-Clamp is proved to effectively reduce severity of canine mitral valve regurgitation, and the operation is performed through a small apical incision , which greatly improves the safety of the operation.

Company Profile



Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicating to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the self-developed mitral valve Interventional repair device V-CLAMP.

It is the leading surgical instrument around the world which can be used to treat mitral regurgitation for pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.

V-CLAMP devices have successfully launched in hospitals and institutions from home and abroad.

GLOBAL FOOTPRINT



Hongyu medical is currently cooperating with many top universities and scientific research institutions in the field of pet therapy in the world.
























Related Study





Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs

Bo Liu¹, Stacey B. Leach², Wershi Pan², Fangyu Zheng², Liujun Jia⁴, Xueying Zhou¹ and

Background: Veterinary management of mitral valve regurgitation due to misyomatou valve disease in dogs is limited to medical treatments, which only postpones the onsel of congestive heart fallure or alleviates clinical symptoms. Most surgical procedures to manage this condition in humans require cardiopulmonary bypess and have a high risk

Methods: Prospective observational study. All dogs were treated with a novel

edge-to-edge transcatheter device named ValveClarm. The total surgical procedural time and total catheterization time were recorded. Echocardiographic variables measured pre- and post-procedure were compared using Wilcovin-signed rank test with a P < 0.06Results: The procedural success rate was 100% and all the dogs survived

without complications. The median (interquartle range) total surgical procedural time was 86.5 (76-96.2) minutes and cetheterization time was 23.5 (22-33.8) minutes. Echocardiography revealed a significant reduction in mitral regurgitation severity in all dogs following the procedure based on both a reduced mitral regurgitant maximum jet area (P = 0.012) and a reduced mitral regurgitant maximum jet area to left atrial area (P = 0.018).

Conclusion: The VelveClamp device is effective at reducing the severity of mitral regurgitation in dogs with naturally occurring mynomatous valve disease

INTRODUCTION

Mysomatous mittal valve disease (MMVD) is the most common cardiac disease in dogs, primarily affecting, small breeds (1). The standard care for this disease is primarily medical therapy, while sungical treatment is performed in a minority of dogs (2). Medical therapy postpones the onset of congestive hant fadure (GIF), and also increases the surrows time once CIF develope

More cases



Weight: 7.3KG MMVD: B2



Age: 10 Weight: 9.1KG MMVD: C



MMVD: C



Weight: 4KG MMVD: C



Age: 12 Weight: 3.2KG MMVD: C



Weight: 5KG MMVD: D